CAMBRIDGE, Mass., Oct. 27 /PRNewswire-FirstCall/ -- Genzyme Corporation
(Nasdaq: GENZ) announced today that it has extended its offer to acquire
the outstanding shares of AnorMED Inc. (Nasdaq: ANOR; TSX: AOM) of
Vancouver, British Columbia until 8:00 a.m. Vancouver time on November 7,
2006. Prior to this extension, Genzyme's offer was set to expire at 8:00
a.m. Vancouver time on November 6, 2006. Genzyme extended its offer after
receiving confirmation that the applicable waiting period under the
Hart-Scott-Rodino Antitrust Improvements Act of 1976 is expected to expire
at 11:59 p.m. New York City time on November 6, 2006, unless the Federal
Trade Commission requests additional information or grants early
termination.
Genzyme announced on October 17, 2006 that it had entered into a
support agreement with AnorMED under which Genzyme will acquire AnorMED in
an all cash transaction valued at $13.50 per outstanding share, or
approximately $580 million. Genzyme may elect to extend its offer again by
giving notice of such extension to AnorMED shareholders, a copy of which
will be filed with the securities regulatory authorities in Canada and the
United States and which should also be made available by such authorities
through the Internet at http://www.sedar.com or http://www.sec.gov. As of
9:00 a.m. New York City time on October 27, 2006, approximately 52,468
AnorMED shares had been tendered and not withdrawn to Genzyme's offer.
About Genzyme
One of the world's leading biotechnology companies, Genzyme is
dedicated to making a major positive impact on the lives of people with
serious diseases. This year marks the 25th anniversary of Genzyme's
founding. Since 1981, the company has grown from a small start-up to a
diversified enterprise with more than 8,500 employees in locations spanning
the globe and 2005 revenues of $2.7 billion. Genzyme has been selected by
FORTUNE as one of the "100 Best Companies to Work for" in the United
States.
With many established products and services helping patients in more
than 80 countries, Genzyme is a leader in the effort to develop and apply
the most advanced technologies in the life sciences. The company's products
and services are focused on rare inherited disorders, kidney disease,
orthopedics, cancer, transplant and immune diseases, and diagnostic
testing. Genzyme's commitment to innovation continues today with a
substantial development program focused on these fields, as well as heart
disease and other areas of unmet medical need.
Important Information Regarding the Tender Offer
Investors and security holders are urged to read the disclosure
documents filed with the Securities and Exchange Commission (the "SEC")
from time to time, including the tender offer statement filed on September
1, 2006, as amended, regarding the tender offer by Genzyme's wholly owned
subsidiary, Dematal Corp., for all of the outstanding common shares of
AnorMED. Investors and security holders may obtain a free copy of the
disclosure documents and other documents filed by Genzyme or Dematal with
the SEC at the SEC's website at http://www.sec.gov. In addition, documents filed
with the SEC by Genzyme or
Dematal may be obtained free of charge from Genzyme by directing a
request to Sally Curley at (617) 768-6140.
Genzyme(R) is a registered trademark of Genzyme Corporation. All rights
reserved.
Genzyme's press releases and other company information are available at
http://www.genzyme.com and by calling Genzyme's investor information line
at 1-800-905-4369 within the United States or 1-703-797-1866 outside the
United States.
Media Contact: Investor Contact:
Dan Quinn Sally Curley
(617) 768-6849 (617) 768-6140
SOURCE Genzyme Corporation
 back to top
Related links:
http://www.genzyme.com
http://www.prnewswire.com/comp/113803.html /
CONTACT:
Media Contact: Dan Quinn, +1-617-768-6849, or
Investor Contact: Sally Curley, +1-617-768-6140, both of Genzyme
|
